A novel assay for influenza virus quantification using surface plasmon resonance.

Quantification of hemagglutinin (HA) by single-radial immuno diffusion (SRID) is the predominant method to ensure product potency in seasonal influenza vaccines. Here a new method for quantification of influenza virus using biosensor technology is presented. The method employs quantification of virus via an inhibition assay format using HA proteins for H1N1, H3N2 and B immobilized on a sensor chip. Initial results showed the assay to have higher sensitivity (detection range 0.5-10 microg/ml), higher precision and significantly lower analysis and hands on time compared with SRID.

Predicting the intestinal absorption potential of hits and leads.

Today's pharma environment requires rapid and reliable methods of screening drug leads for intestinal permeability potential in the early stages of drug discovery. Techniques using excised tissues, Caco-2 cells, artificial membranes, 'in silico' techniques and surface plasmon resonance (SPR)-based biosensors are critically examined in terms of their reliability, measurement criteria, throughput and utility in identifying potentially successful or unsuccessful drug molecules.:

Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space.

A multivariate approach involving modifications in peptide sequence and chemical buffer medium was used as an attempt to predict the kinetics of peptide-antibody interactions. Using a BIACORE system the kinetic parameters of the interaction of Fab 57P with 18 peptide analogues of an epitope of tobacco mosaic virus protein were characterized in 20 buffers of various pH values and containing different chemical additives (NaCl, urea, EDTA, KSCN and DMSO). For multivariate peptide design, three amino acid positions were selected because their modification was known to moderately affect binding, without abolishing it entirely. Predictive mathematical models were developed which related kinetic parameters (k(a) or k(d)) measured in standard buffer to the amino acid sequence of the antigen. ZZ-scales and a helix-forming-tendency (HFT) scale were used as descriptors of the physico-chemical properties of amino acids in the peptide antigen. These mathematical models had good predictive power (Q(2) = 0.49 for k(a), Q(2) = 0.73 for k(d)). For the non-essential residues under study, HFT and charge were found to be the most important factors that influenced the activity. Experiments in 19 buffers were performed to assess the sensitivity of the interactions to buffer composition. The presence of urea, DMSO and NaCl in the buffer influenced binding properties, while change in pH and the presence of EDTA and KSCN had no effect. The chemical sensitivity fingerprints were different for the various peptides. The results indicate that multivariate experimental design and mathematical modeling can be applied to the prediction of interaction kinetics.

Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen.

The interaction between 290 structurally diverse human immunodeficiency virus type 1 (HIV-1) protease inhibitors and the immobilized enzyme was analyzed with an optical biosensor. Although only a single concentration of inhibitor was used, information about the kinetics of the interaction could be obtained by extracting binding signals at discrete time points. The statistical correlation between the biosensor binding data, inhibition of enzyme activity (K(i)), and viral replication (EC(50)) revealed that the association and dissociation rates for the interaction could be resolved and that they were characteristic for the compounds. The most potent inhibitors, with respect to K(i) and EC(50) values, including the clinically used drugs, all exhibited fast association and slow dissociation rates. Selective or partially selective binders for HIV-1 protease could be distinguished from compounds that showed a general protein-binding tendency by using three reference target proteins. This biosensor-based direct binding assay revealed a capacity to efficiently provide high-resolution information on the interaction kinetics and specificity of the interaction of a set of compounds with several targets simultaneously.

Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors.

The sensitivity of BIACORE technology is sufficient for detection and characterization of binding events involving low-molecular-weight compounds and their immobilized protein targets. The technology requires no labeling and provides information on the stability of the compound/target complex with a single injection of the compound. This is useful for qualifying hits obtained in a primary screen and in lead optimization. Although immobilized targets can be reused, the surface may slowly deteriorate, solvent effects can distort binding levels during injection of compounds, and some compounds may exhibit broad protein selectivity rather than target specificity. A reliable direct binding assay for compounds binding to immobilized thrombin using a combination of two reference surfaces, a dextran surface for subtraction and calibration of solvent effects and a protein surface for identification of compounds that tend to bind proteins, has been developed. Eleven compounds with known binding specificity to thrombin and 159 additional compounds were investigated. All compounds with known binding specificity were identified at 1 and 10 microM concentration. One additional compound was scored as positive. The direct binding assay compared favorably with two competitive assay formats, a surface competitive assay and a inhibitor in solution assay, that were examined in parallel.